ICICI Direct has given Buy recommendation for Suven Pharmaceuticals with a target price of Rs. 650 in its research report issued on Aug 16, 2021

ICICI Direct’s research report on Suven Pharmaceuticals

Suven Pharma is a CDMO that supports global life sciences industry & fine chemical majors in their NCE development endeavours. Its services include custom synthesis, process R&D, scale-up & contract manufacturing. Business comprises three segments – CDMO (development projects and commercial supplies), specialty chemicals and contract technical service CDMO vertical contributes more than 62% of its topline. Owing to its CDMO competence, it has developed & supplies intermediates for two specialty chemical products (agrochemical) to large global conglomerates

Outlook

We retain our BUY rating on this stock We value Suven at Rs 650 with 32x P/E on FY23E EPS

 

Leave a Reply

Your email address will not be published. Required fields are marked *